Skip to main content

Vaccine for prevention and treatment of Trypanosoma cruzi infection

Project description

A new vaccine for the killer disease Chagas

Vector-borne diseases, spread by organisms such as pathogen-carrying insects, account for more than 17 % of all infectious diseases and they disproportionately affect people in the poorest populations. One of those is Chagas disease, prevalent mainly in Latin American countries. In severe cases, Chagas disease can cause congestive heart failure and cardiac arrest. CRUZIVAX is taking a needle-free vaccine candidate from preclinical trials in mice through to a Phase I clinical trial in healthy volunteers. Even better, the study includes low-cost manufacturing and a health economics analysis to support widespread access by healthcare systems in poor countries that are the most vulnerable.

Call for proposal

H2020-SC1-2018-Two-Stage-RTD
See other projects for this call

Coordinator

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Address
Inhoffenstrasse 7
38124 Braunschweig
Germany
Activity type
Research Organisations
EU contribution
€ 2 070 198,15

Participants (10)

UNIVERSIDAD DE BUENOS AIRES
Argentina
EU contribution
€ 745 500
Address
Calle Viamonte 430
1053 Buenos Aires
Activity type
Higher or Secondary Education Establishments
UNIVERSIDADE NOVA DE LISBOA
Portugal
EU contribution
€ 442 206,25
Address
Campus De Campolide
1099 085 Lisboa
Activity type
Higher or Secondary Education Establishments
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
EU contribution
€ 963 795,49
Address
Rue Leblanc 25
75015 Paris 15
Activity type
Research Organisations
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Portugal
EU contribution
€ 352 356,64
Address
Avenida Da Republica Quinta Do Marques
2781-901 Oeiras
Activity type
Research Organisations
GENIBET - BIOPHARMACEUTICALS SA
Portugal
EU contribution
€ 861 249,50
Address
Avenida Da Republica Quinta Do
2781 901 Oeiras
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASA SPEZIALENZYME GMBH
Germany
EU contribution
€ 951 500
Address
Am Exer 19 C
38302 Wolfenbuttel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ATRC AURIGON TOXICOLOGIAI KUTATOKOZPONT KORLATOLT FELELOSSEGU TARSASAG
Hungary
EU contribution
€ 863 592,50
Address
Palya Utca 2
2120 Dunakeszi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITEIT ANTWERPEN
Belgium
EU contribution
€ 577 302,76
Address
Prinsstraat 13
2000 Antwerpen
Activity type
Higher or Secondary Education Establishments
FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA
Spain
EU contribution
€ 253 401,50
Address
C Rossello 132 Planta 05
08036 Barcelona
Activity type
Research Organisations
VAKZINE PROJEKT MANAGEMENT GMBH
Germany
EU contribution
€ 310 137,50
Address
Mellendorfer Strasse 9
30625 Hannover
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)